Skip to main content
Unchecking box will stop auto data updates
Cboe BZX Real-Time Last Sale USD
Today's Change
Volume
Price Quote as of

Today's Trading

Day Low 16.25
Day High 16.80
Open:16.46
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

More stories below advertisement

FEATURE-EMPTY
Description
Moderna Inc. is a clinical stage biotechnology company pioneering messenger RNA therapeutics and vaccines for patients. The company's product pipeline which is in clinical stage consists of mRNA-1647 for Cytomegalovirus Infectious Disease, mRNA-4157 for Solid tumors, mRNA-2416 for lymphoma and mRNA- 2752 for Relapsed/Refractory solid tumors malignancies. Moderna Inc. is based in Cambridge, United States.

Fundamentals

Market Capitalization, $M
Shares Outstanding, M
36-Month Beta
Earnings Per Share (TTM)
Revenue Growth YoY
Profit Margin
5-Year Avg. Revenue Growth
5-Year Avg. Profit Growth
1-Year Total Return
3-Year Total Return
5-Year Total Return
Price/Earnings (TTM)
Price/Earnings (Forward)
Trailing Annual Dividend & Yield
Forward Annual Dividend & Yield
Most Recent Dividend
Ex-Div Date
Most Recent Split
Return on Common Equity
Return-on-Assets (Before Tax)
Debt-to-Equity Ratio
Price/Book

Earnings

Corporate earnings are provided from Zacks Investment Research, including Income Statements, Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.

Analyst Research

Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research – including Buy/Hold Recommendations, Earnings Surprises, Estimates and Recommendations History.

Stock Reports +

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

StockCalc Reports

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

Latest Press Releases

Dr. John Mendlein to Transition to an Advisory Role at Moderna and Join Flagship Pioneering as an Executive Partner
BusinessWire - Fri Jan 18, 7:00AM CST
BusinessWire - CMTX
Fri Jan 18, 7:00AM CST
Moderna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that John Mendlein, Ph.D., President of Corporate and Product Strategy, will be leaving the Company effective February 1, 2019 to join Flagship Pioneering as an Executive Partner. He will be a strategic consultant to Moderna for six months to ensure a smooth transition.
Why Clinical Trial Advantages and Regulatory Process in EU may Hold Advantages Over the U.S.
PR Newswire - Wed Jan 9, 7:30AM CST
PR Newswire - CMTX
Wed Jan 9, 7:30AM CST
Financialnewsmedia.com News Commentary
Moderna Announces Recent Progress in Its Immuno-Oncology and Rare Disease Programs and Highlights Corporate Objectives
BusinessWire - Tue Jan 8, 7:30AM CST
BusinessWire - CMTX
Tue Jan 8, 7:30AM CST
--IND amendment submitted to the FDA for a Phase 2 cohort of OX40L (mRNA-2416) to treat advanced ovarian carcinoma
Price History Describes more index sector components

Price Performance

Period Period Low Period High Performance
1-Month 13.03 +28.09% increase
on 12/26/18
Period Open:17.00
Price movement based on the high, low and last over the given period.
17.94 -6.97% decrease
on 01/07/19
-0.31 (-1.82%) decrease
since 12/18/18
3-Month 13.03 +28.09% increase
on 12/26/18
Period Open:18.60
Price movement based on the high, low and last over the given period.
22.75 -26.64% decrease
on 12/07/18
-1.91 (-10.27%) decrease
since 12/07/18
52-Week 13.03 +28.09% increase
on 12/26/18
Period Open:18.60
Price movement based on the high, low and last over the given period.
22.75 -26.64% decrease
on 12/07/18
-1.91 (-10.27%) decrease
since 12/07/18

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2019.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

More stories below advertisement